Combining D-cycloserine and exposure-based CBT for the anxiety disorders

Clinical Neuropsychiatry

Volumn 6, Issue 2, 2009, Pages 75-82

  Deveney, Christen M ^a   McHugh, Kathryn R ^a   Tolin, David F ^b   Pollack, Mark H ^c   Otto, Michael W ^a  

^a BOSTON UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anxiolysis; Cognitive behavior therapy; Combination treatments; D cycloserine; Glutamatergic N Methyl D Aspartate

Indexed keywords

CYCLOSERINE; FLUOXETINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PLACEBO; YOHIMBINE;

ACROPHOBIA; ALZHEIMER DISEASE; ANXIETY DISORDER; BASIC RESEARCH; CHRONIC DRUG ADMINISTRATION; CLAUSTROPHOBIA; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; DIZZINESS; DOSE RESPONSE; DRUG ABUSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TOLERABILITY; FATIGUE; FEAR; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; NEGATIVE SYNDROME; NIGHTMARE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PHOBIA; PROTEIN FUNCTION; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; REINFORCEMENT; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; SOCIAL PHOBIA; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 68249148296     PISSN: 17244935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Anderson KC, Insel TR (2006). The Promise of Extinction Research for the Prevention and Treatment of Anxiety Disorders. Biological Psychiatry 60, 4, 319-321.
2. Bailey JE, Papdopoulos A, Lingford-Hughes A, Nutt DJ (2007). D-cycloserine and performance under different states of anxiety in healthy volunteers. Psychopharmacology (Berl) 193, 4, 579-585.
3. Barlow DH, Craske MG, Meadows EA (2000). Mastery of your anxiety and panic (third edition): Therapist guide for anxiety, panic, and agoraphobia. Oxford University Press, Oxford.
4. Bouton ME, Westbrook RF, Corcoran KA, Maren S (2006). Contextual and temporal modulation of extinction: behavioral and biological mechanisms. Biological Psychiatry 60, 352-360.
5. Bouton ME, Vurbic D, Woods AM (2008). D-cycloserine facilitates context-specific fear extinction learning. Neurobiology of Learning and Memory 90, 504-510.
6. Cahill L, Gorski L, Le K (2003). Enhanced human memory consolidation with post-learning stress: interaction with the degree of arousal at encoding. Learning and Memory 10, 4, 270-274.
7. Cain CK, Blouin AM, Barad M (2004). Adrenergic transmission facilitates extinction of conditional fear in mice. Learning and Memory 11, 2, 179-187.
8. Clark DM, Salkovskis PM, Hackmann A, Wells A, Ludgate J, Gelder M (1999). Brief cognitive therapy for panic disorder: a randomized controlled trial. Journal of Consulting and Clinical Psychology 67, 583-9.
9. Craske MG, Maidenberg E, Bystritsky A (1995). Brief cognitive-behavioral versus nondirective therapy for panic disorder. Journal of Behavior Therapy and Experimental Psychiatry 26, 113-120.
10. Davidson JRT, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM (2004). Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry 51, 1005-1013.
11. Davis M (2002). Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: Clinical implications for exposure therapy. European Journal of Neuroscience 16, 395-398.
12. D'Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH (2000). IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biological Psychiatry 47, 450-462.
13. Furukawa TA, Watanabe N, Churchill R (2006). Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. British Journal of Psychiatry 188, 305-312.
14. Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, Schoenfeld D, Green MF (2008). Once-weekly d-cycloserine effects on negative symptoms and in schizophrenia: An exploratory study. Schizophrenia Research 106, 320-327.
15. Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R (2007a). A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. Journal of Psychiatric Research 41, 6, 466-471.
16. Guastella AJ, Lovibond PF, Dadds MR, Mitchell P, Richardson R (2007b). A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. Behaviour Research and Therapy 45, 663-672.
17. Guastella AJ, Richardson R., Lovibond PF, Rapee, RM., Gaston, J.E., Mitchell P, & Dadds MR (2008). A randomized controlled trial of the effect of D-cycloserine on enhancement of exposure therapy for social anxiety disorder. Biological Psychiatry 63, 544-549.
18. Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, Blanaru M, Cohen T (2002). Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. International Journal of Neuropsychopharmacology 5, 301-307.
19. Herry C, Garcia R. (2002). Prefrontal cortex long-term potentiation, but not long-term depression, is associated with the maintenance of extinction of learned fear in mice. Journal of Neuroscience 22, 577-583.
20. Hofmann SG, Meuret AE, Smits JAJ, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW (2006). Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Archives of General Psychiatry 63, 298-304.
21. Hofmann SG, Otto MW (2008). Cognitive behavior therapy for social anxiety disorder: Evidence - based and disorder-specific treatment techniques. Routledge, New York.
22. Katzelnick DJ, Kobak KA, DeLeire T, Henk HJ, Greist JH, Davidson JRT, Schneier FR, Stein MB, Helstad CP (2001). Impact of generalized social anxiety disorder in managed care. American Journal of Psychiatry 158, 1999-2007.
23. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe, Peterson J, Foa EB (2007). D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry 62, 835-838.
24. Laake K, Oeksengaard AR (2002). D-cycloserine for Alzheimer's disease. Cochrane Database Systematic Reviews. CD003153
25. Land C, Riccio D (1999). D-cycloserine: Effects, on long-term retention of a conditioned response and on memory for contextual attributes. Neurobiology of Learning and Memory 72, 3, 158-168.
26. Langton JM, Richardson R (2008). D-cycloserine facilitates extinction the first time but not the second time: an examination of the role of NMDA across the course of repeated extinction sessions. Neuropsychopharmacology 33, 3096-3102.
27. Ledgerwood L, Richardson R, Cranney J (2003). Effects of D-cycloserine on extinction of conditioned freezing. Behavioral Neuroscience 117, 341-349.
28. Ledgerwood L, Richardson R, Cranney J (2004). D-cycloserine and the facilitation of conditioned fear: Consequences for reinstatement. Behavioral Neuroscience 118, 505-513.
29. Lelong V, Dauphin F, Boulouard M (2001). RS 67333 and D-cycloserine accelerate learning acquisition in the rat. Neuropharmacology 41, 517-522.
30. Milad MR, Quirk GJ (2002). Neurons in medial prefrontal cortex signal memory for fear extinction. Nature 420, 70-74.
31. Monahan JB, Handelmann GE, Hood WF, Cordi AA (1989). D-cycloserine, a positive modulator of the Nmethyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacology, Biochemistry and Behavior 34, 649-653.
32. Monti PM, Rohsenow DJ, Rubonis AV, Niaura RS, Sirota AD, Colby SM, Abrams DB (1993). Alcohol cue reactivity: Effects of detoxification and extended exposure. Journal of Studies on Alcohol 54, 2, 235-245.
33. Myers KM, Davis M (2002). Behavioral and neural analysis of extinction. Neuron 36, 567-584.
34. Norberg MM, Krystal JH, & Tolin DF (2008). A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry 63, 12, 1118-1126.
35. Orr SP, Metzger LJ, Lasko NB, Macklin ML, Peri T, Pitman RK (2000). De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. Journal of Abnormal Psychology 109, 290-298
36. Otto MW, Basden SL, McHugh RK, Kantak KM, Deckersbach T, Cather C, Goff DC, Hofmann SG, Berry AC, Smits JA (2009). Effects of D-Cycloserine administration on weekly nonemotional memory tasks in healthy participants. Psychotherapy and Psychosomatics 78, 49-54.
37. Otto MW, Basden SL, Leyro TM, McHugh RK, Hofmann SG (2007). Clinical perspectives on the combination of d-cycloserine and CBT for the treatment of anxiety disorders. CNS Spectrums 12, 51-61.
38. Otto MW, O'Cleirigh CM, Pollack MH (2007). Attending to emotional cues for drug use: Bridging the gap between clinic and home behavior. NIDA Science and Practice Perspectives April, 48-55.
39. Otto MW, Smits JAJ, Reese HE (2005). Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: Review and analysis. Clinical Psychology: Science and Practice 12, 72-86.
40. Öst LG (1996). One-session group treatment of spider phobia. Behavior Research and Therapy 34, 707-715.
41. Paolone G, Botreau F, Stewart K (2009). The facilitative effects of d-cycloserine on extinction of cocaine-induced conditioned place preference can be long lasting and resistant to reinstatement. Psychopharmacology Berl 202, 403-409.
42. Parnas AS, Weber M, Richardson R. (2005). Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiology of Learning and Memory 83, 224-231.
43. Pitkanen M, Sirvio J, MacDonald E, Niemi S, Ekonsalo T, Riekkinen P Sr (1995). The effects of D-cycloserine and MK-801 on the performance of rats in two spatial learning and memory tasks. European Neuropsychopharmacology 5, 4, 457-63.
44. Powers MB, Smits JAJ, Otto MW, Sanders C, & Emmelkamp P (2009). Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: A randomized placebo controlled trial of yohimbine augmentation. Journal of Anxiety Disorders 23, 350-356.
45. Pussinen R, Sirvio J (1999). Effects of d-cycloserine, a positive modulator of N-methyl-D-aspartate receptors, and ST 587, a putative alpha-1 adrenergic agonist, individually and in combination, on the non-delayed and delayed foraging behaviour of rats assessed in the radial arm maze. Journal of Psychopharmacology 13, 171-179.
46. Randolph C, Roberts JW, Tierney MC, Bravi D, Mouradian MM, Chase TN (1994). D-cycloserine treatment of Alzheimer disease. Alzheimer Disease & Associated Disorders 8, 198-205.
47. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M (2004). Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobics to facilitate extinction of fear. Archives of General Psychiatry 6-1, 1136-1144.
48. Richardson R, Ledgerwood L, Cranney J (2004). Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learning and Memory 11, 510-516.
49. Rodrigues SM, Schafe GE, LeDoux JE (2001). Intra-amygdala blockade of the NR2B subunit of the NMDA receptor disrupts the acquisition but not the expression of fear conditioning. Journal of Neuroscience 21, 6889-6896.
50. Roozendaal B, Hui GK, Hui IR, Berlau DJ, McGaugh JL, Weinberger NM (2006). Basolateral amygdala noradrenergic activity mediates corticosterone-induced enhancement of auditory fear conditioning. Neurobiology of Learning and Memory 86, 3, 249-255.
51. Roy-Byrne PP, Craske MG, Stein MB, Sullivan G, Bystritsky A, Katon W, Golinelli D, Sherbourne CD (2005). A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Archives of General Psychiatry 62, 290-8.
52. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH (1994). Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. European Journal of Pharmacology 157, 7-12.
53. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon B, Gitow A, Street L, DelBene D, Liebowitz MR (1994). Functional impairment in social phobia. Journal of Clinical Psychiatry 55, 322-331.
54. Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, Roozendaal, B deQuervain DJF (2006). Glucocorticoids reduce phobic fear in humans. Proceedings of the National Academy of Sciences USA 103, 14, 5585-5590.
55. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M, Geffken GR, Goodman WK (2007). D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology 22, 230-237.
56. Tuominen HJ, Tiihonen J, Wahlbeck K (2005). Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis. Schizophrenia Research 72, 225-234.
57. Walker DL, Ressler KJ, Lu KT, Davis M (2002). Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear- potentiated startle in rats. Journal of Neuroscience 22, 2343-2351.
58. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jennike MA, Rauch SL (2008). Augmentation of Behavior Therapy with D-Cycloserine for Obsessive-Compulsive Disorder. American Journal of Psychiatry 165, 335-341.
59. van Berckel BN, Lipsch C, Gispen-de Wied C, Wynne HJ, Blankenstein MA, van Ree JM, Kahn RS (1998). The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berl) 138, 190-197.
60. van Berckel BN, Lipsch C, Timp S, Gispen-de Wied C, Wynne H, van Ree JM., Kahn RS (1997). Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology 16, 317-324.
61. Vengeliene V, Kiefer F, Spanagel R (2008). D-cycloserine facilitates extinction of conditioned alcohol-seeking behaviour in rats. Alcohol and Alcoholism 43, 626-629.
62. Yang YL, Chao PK, Ro LS, Wo YY, Lu KT (2007). Glutamate NMDA receptors within the amygdala participate in the modulatory effect of glucocorticoids on extinction of conditioned fear in rats. Neuropsychopharmacology 32, 5, 1042-1051.